Disclosed is a compound of formula (V) where the substituents are as disclosed in the description. Also disclosed is the use of a compound of formula (V) in the manufacture of a medicament for inhibiting or preventing alpha-synuclein toxicity and/or fibril formation, inhibiting or preventing alpha-synuclein fibril growth, and/or causing disassembly, disruption, and/or disaggregation of alpha-synuclein fibrils and a-synuclein-associated protein deposits. Examples of compound of formula (V) include N-[1-(1H-benzimidazol-2-yl)-3-methyl-1H-pyrazol-5-yl]-4-chlorobenzamide and Ethyl{ [1-(1H-benzimidazol-2-yl)-3-methyl-1H-pyrazol-5-yl]amino} (oxo)acetate. Further disclosed is a composition comprising a compound of formula (V).
